| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04615949 Details | 2022-12-14 Interventional | 2/3 | 90 | Cannabidiol COVID-19 Cardiovascular … Cardiovascular … | The changing nature of COVID-19 including a more vaccinated population, increasing natural
population immunity, milder variants and other related factors has meant that it is no longer
realistic to recruit the patients in a reasonable time frame. - | |||
| NCT03781960 Details | 2022-12-14 Interventional | 2 | 7 | Nivolumab Carcinoma Carcinoma, Hepa… Hepatocellular … | Safety letter from sponsor Early termination leading to small numbers of subjects analyzed | |||
| NCT03052725 2016-004661-23 Details | 2022-12-14 Interventional | 3 | 391 | Reslizumab Asthma Pulmonary Eosin… Eosinophils, As… | Parent Studies didn't meet their primary endpoint so study was terminated. - | |||
| NCT04984798 Details | 2022-12-13 Interventional | 2 | 0 | Tocopherols Vitamin E alpha-Tocophero… Hyperammonemia Hyperinsulinism Syndrome Hyperinsulinism… | No study activity took place. The IND was withdrawn with the FDA by the Sponsor Investigator
because of insurmountable hurdles in moving proposed research forward - | |||
| NCT04372706 Details | 2022-12-13 Interventional | 1/2 | 69 | Pembrolizumab Solid Tumor, AM… | Sponsor terminated study during expansion on 11/30/22. RTX-240 was well-tolerated in multiple
indications, combinations, and dose levels (69pts). No DLTs, related deaths or SAEs were
reported. RTX-240 cleared circulation rapidly. - | |||
| NCT02975999 Details | 2022-12-13 Interventional | 2/3 | 0 | Arginine Vasopr… Vasopressins Pleural Effusio… Univentricular … Single-ventricl… | Pilot study is finished, multi centered is not moving forward - | |||
| NCT04810494 Details | 2022-12-12 Interventional | 4 | 0 | Lidocaine Nausea Postoperative N… Vomiting | Change in study team - | |||
| NCT04464512 Details | 2022-12-12 Interventional | 4 | 0 | Buprenorphine Sufentanil Chronic Pain Fractures, Bone Addiction Opiat… Buprenorphine D… | No qualified enrollments; study cancelled due to pandemic - | |||
| NCT04001647 Details | 2022-12-12 Interventional | 1 | - | Acetylcholine Ascorbic Acid Nitroprusside Arterial Stiffn… Vasodilation | IRB approval has been withdrawn - | |||
| NCT03563222 Details | 2022-12-12 Interventional | 4 | 1 | SMOFlipid Soybean oil, ph… Child Nutrition… Malnutrition Malnutrition, C… | Prematurely stopped in agreement with authorities (FDA) The study was released from postmarketing requirement and the product received marketing authorization approval from the U.S. Food & Drug Administration. Therefore, the study was early terminated after treatment of a single patient. | |||
| NCT03262116 Details | 2022-12-09 Interventional | 2/3 | 20 | Insulin Insulin Aspart Insulin Lispro Insulin, Globin… Pancrelipase Diabetes Mellit… Type 1 Diabetes… | Devices are not available The study was terminated, so only a limited number of participants completed all three interventions. | |||
| NCT04956302 Details | 2022-12-08 Interventional | 1 | 1 | Antibodies, Mon… BB 1101 Bortezomib Daratumumab Dexamethasone Dexamethasone a… Ichthammol Panobinostat Multiple Myelom… Neoplasms, Plas… Recurrent Plasm… Refractory Plas… | PI Decision - | |||
| NCT04823052 Details | 2022-12-08 Interventional | 2 | 0 | Gaboxadol Sulindac Fragile X Syndr… Syndrome | Healx has experienced delays to the site activation of the study and this has had an adverse
impact on the recruitment timeline which is delaying the progress of other projects in our FXS
programme. - | |||
| NCT05312372 2022-000250-29 Details | 2022-12-07 Interventional | 1/2 | 0 | Paclitaxel Carcinoma Carcinoma, Squa… Esophageal Squa… | Strategic development reasons - | |||
| NCT04294836 Details | 2022-12-07 Interventional | 2 | [7 Refs] | 0 | Curcumin Uterine Cervica… Cervical Cancer… | Issues with local regulatory authority - | ||
| NCT03815682 Details | 2022-12-06 Interventional | 1 | 23 | Pembrolizumab Lymphoma Solid Tumor | Development program terminated - | |||
| NCT02939365 Details | 2022-12-06 Interventional | 4 | 0 | Abatacept Transplantation | Because of inability to get FDA approval for - | |||
| NCT05325164 Details | 2022-12-05 Interventional | 3 | 0 | Methadone Morphine Adenocarcinoma Cancer Pain | Trial not started; change in Sponsor and Principal Investigator, trial to be registered again
by new Sponsor/Investigator if it is started. - | |||
| NCT05020483 Details | 2022-12-05 Interventional | 2 | 0 | Anti-inhibitor … Heart Diseases Cardiac Disease | Patient population changed and no subjects eligible for the study. - | |||
| NCT02703272 2016-000259-28 Details | 2022-12-02 Interventional | 3 | 72 | Carboplatin Dexamethasone Etoposide Ibrutinib Idarubicin Ifosfamide Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… | IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value
crossed the futility boundary specified in protocol (July 2020). - |